{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:32:10Z","timestamp":1779179530607,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1196-6","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T11:05:47Z","timestamp":1481627147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis"],"prefix":"10.1186","volume":"18","author":[{"given":"Anastasiya","family":"Muntyanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Abji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy A.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"1196_CR1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2009","unstructured":"Reich K, Kr\u00fcger K, M\u00f6ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040\u20137.","journal-title":"Br J Dermatol."},{"key":"1196_CR2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","volume":"24","author":"E Christophers","year":"2010","unstructured":"Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548\u201354.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1196_CR3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","volume":"71","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Gladman DD, Helliwell P, Khraishi MM, Fuiman J, Bananis E, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2014;71:649\u201355.","journal-title":"J Am Acad Dermatol."},{"key":"1196_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/17512433.2014.904200","volume":"7","author":"S Varada","year":"2014","unstructured":"Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol. 2014;7:239\u201350.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"1196_CR5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11926-012-0263-5","volume":"14","author":"WJ Taylor","year":"2012","unstructured":"Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep. 2012;14:369\u201374.","journal-title":"Curr Rheumatol Rep."},{"key":"1196_CR6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","volume":"72","author":"M Haroon","year":"2013","unstructured":"Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72:736\u201340.","journal-title":"Ann Rheum Dis."},{"key":"1196_CR7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Kraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729\u201335.","journal-title":"J Am Acad Dermatol."},{"key":"1196_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2014.414","volume":"135","author":"RA Pollock","year":"2015","unstructured":"Pollock RA, Abji F, Liang K, Chandran V, Pellett FJ, Virtanen C, et al. Gene expression differences between psoriasis patients with and without inflammatory arthritis. J Invest Dermatol. 2015;135:620\u20132.","journal-title":"J Invest Dermatol."},{"key":"1196_CR9","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/ar1997","volume":"8","author":"P Proost","year":"2006","unstructured":"Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, et al. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergizing inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther. 2006;8:R107.","journal-title":"Arthritis Res Ther."},{"key":"1196_CR10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.184.3.963","volume":"184","author":"M Loetscher","year":"1996","unstructured":"Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP-10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:963\u20139.","journal-title":"J Exp Med."},{"key":"1196_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/eji.1830270117","volume":"27","author":"MA Cassatella","year":"1997","unstructured":"Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP. Regulated production of the interferon-\u03b3-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol. 1997;27:111\u20135.","journal-title":"Eur J Immunol."},{"key":"1196_CR12","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.4049\/jimmunol.162.8.4928","volume":"162","author":"S Gasperini","year":"1999","unstructured":"Gasperini S, Marchi M, Calzetti F, Bertagnin A, Luster AD, McDonald PP. Gene expression and production of the monokine induced by IFN-\u03b3 (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-\u03b3-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol. 1999;162:4928\u201337.","journal-title":"J Immunol."},{"key":"1196_CR13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0167-5699(98)01346-2","volume":"19","author":"F Sallusto","year":"1998","unstructured":"Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1\/Th2-mediated responses. Immunol Today. 1998;19:568\u201374.","journal-title":"Immunol Today."},{"key":"1196_CR14","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","volume":"68","author":"F Abji","year":"2016","unstructured":"Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 2016;68:2911\u20136.","journal-title":"Arthritis Rheumatol."},{"key":"1196_CR15","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum."},{"key":"1196_CR16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101\u20138.","journal-title":"Nat Protoc."},{"key":"1196_CR17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(15)61170-9","volume":"386","author":"P Helliwell","year":"2015","unstructured":"Helliwell P, Coates L. Interleukin-17 inhibition in psoriatic arthritis. Lancet. 2015;386:1114\u20136.","journal-title":"Lancet."},{"key":"1196_CR18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet."},{"issue":"5 Suppl 51","key":"1196_CR19","first-page":"S62","volume":"26","author":"DD Gladman","year":"2008","unstructured":"Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S62\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1196_CR20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1196_CR21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3899\/jrheum.150466","volume":"43","author":"Z Touma","year":"2016","unstructured":"Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook R, Gladman D. Clinical and demographic characteristics of erosion-free and erosion-present status in psoriatic arthritis in a prospective cohort study. J Rheumatol. 2016;43:1057\u201362.","journal-title":"J Rheumatol."},{"key":"1196_CR22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2006.056457","volume":"66","author":"SJ Bond","year":"2007","unstructured":"Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis. 2007;66:370\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1196_CR23","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","volume":"70","author":"DD Gladman","year":"2011","unstructured":"Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70:2152\u20134.","journal-title":"Ann Rheum Dis."},{"key":"1196_CR24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6\u00a0months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045\u201350.","journal-title":"Ann Rheum Dis."},{"key":"1196_CR25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3899\/jrheum.101121","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Inflammatory musculoskeletal disease: identification and assessment. J Rheumatol. 2011;38:557\u201361.","journal-title":"J Rheumatol."},{"issue":"Suppl 3","key":"1196_CR26","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1136\/ard.2006.058453","volume":"65","author":"DD Gladman","year":"2006","unstructured":"Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis. 2006;65 Suppl 3:iii22\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1196_CR27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/art.21736","volume":"54","author":"AL Tan","year":"2006","unstructured":"Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 2006;54:1328\u201333.","journal-title":"Arthritis Rheum."},{"key":"1196_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/keu328","volume":"54","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Hermann KA, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54:29\u201338.","journal-title":"Rheumatology (Oxford)"},{"key":"1196_CR29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272\u201380.","journal-title":"Autoimmun Rev."},{"key":"1196_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2008.07.017","volume":"8","author":"A Antonelli","year":"2008","unstructured":"Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev. 2008;8:18\u201323.","journal-title":"Autoimmun Rev."},{"key":"1196_CR31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1464-5491.2008.02577.x","volume":"25","author":"A Antonelli","year":"2008","unstructured":"Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d\u2019Annunzio G, Lorini R, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed type 1 diabetes: a longitudinal study. Diabet Med. 2008;25:1349\u201353.","journal-title":"Diabet Med."},{"key":"1196_CR32","doi-asserted-by":"crossref","first-page":"R188","DOI":"10.1186\/ar4378","volume":"15","author":"KE Magee","year":"2013","unstructured":"Magee KE, Kelsey CE, Kurzinski KL, Ho J, Mlakar LR, Feghali-Bostwick CA, et al. Interferon-\u03b3 inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res Ther. 2013;15:R188.","journal-title":"Arthritis Res Ther."},{"key":"1196_CR33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.168.3.941","volume":"168","author":"AB Gottlieb","year":"1988","unstructured":"Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a \u03b3 interferon-induced protein IP-10 in psoriatic plaques. J Exp Med. 1988;168:941\u20138.","journal-title":"J Exp Med."},{"key":"1196_CR34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s004030050314","volume":"290","author":"DM Boorsma","year":"1998","unstructured":"Boorsma DM, Flier J, Sampat S, Ottevanger C, de Haan P, Hooft L, et al. Chemokine IP-10 expression in cultured human keratinocytes. Arch Dermatol Res. 1998;290:335\u201341.","journal-title":"Arch Dermatol Res."},{"key":"1196_CR35","first-page":"22","volume":"27","author":"A Antonelli","year":"2009","unstructured":"Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. Clin Exp Rheumatol. 2009;27:22\u20137.","journal-title":"Clin Exp Rheumatol."},{"key":"1196_CR36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2340\/00015555-1545","volume":"93","author":"AK Ekman","year":"2013","unstructured":"Ekman AK, Sigurdardottir G, Carlstr\u00f6m M, Kartul N, Jenmalm MC, Enerback C. Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment. Acta Derm Venereol. 2013;93:527\u201331.","journal-title":"Acta Derm Venereol."},{"key":"1196_CR37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2006.054924","volume":"66","author":"W Hueber","year":"2007","unstructured":"Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66:712\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1196_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/08916934.2014.947476","volume":"48","author":"XT Lima","year":"2015","unstructured":"Lima XT, Oliveira RT, Braga FG, Magalhaes RF, Mamoni RL, Blotta MH. Circulating levels of chemokines in psoriasis. Autoimmunity. 2015;48:57\u201360.","journal-title":"Autoimmunity."},{"key":"1196_CR39","first-page":"e442","volume":"165","author":"A Devito","year":"2014","unstructured":"Devito A. Interferon \u03b3-induced chemokines in psoriatic arthritis. Clin Ter. 2014;165:e442\u20136.","journal-title":"Clin Ter."},{"key":"1196_CR40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","volume":"25","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev. 2014;25:57\u201365.","journal-title":"Cytokine Growth Factor Rev."},{"key":"1196_CR41","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm1202-792","volume":"8","author":"S Frigerio","year":"2002","unstructured":"Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Holl\u00e4nder GA, et al. \u03b2 cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med. 2002;8:1414\u201320.","journal-title":"Nat Med"},{"key":"1196_CR42","doi-asserted-by":"crossref","first-page":"539683","DOI":"10.1155\/2012\/539683","volume":"2012","author":"S Maeda","year":"2012","unstructured":"Maeda S, Hayami Y, Naniwa T, Ueda R. The Th17\/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol. 2012;2012:539683.","journal-title":"Int J Rheumatol."},{"key":"1196_CR43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/eji.200535243","volume":"36","author":"C Ottaviani","year":"2006","unstructured":"Ottaviani C, Nasorri F, Bedini C, de Pit\u00e0 O, Girolomoni G, Cavani A. CD56brightCD16\u2212 NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006;36:118\u201328.","journal-title":"Eur J Immunol."},{"key":"1196_CR44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842\u201355.","journal-title":"Br J Pharmacol."},{"key":"1196_CR45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00296-009-1356-y","volume":"30","author":"T Ichikawa","year":"2010","unstructured":"Ichikawa T, Kageyama Y, Kobayashi H, Kato N, Tsujimura K, Koide Y. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-\u03b3 inducible protein-10 in patients with rheumatoid arthritis. Rheumatol Int. 2010;30:725\u201330.","journal-title":"Rheumatol Int."},{"key":"1196_CR46","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","volume":"175","author":"AB Gottlieb","year":"2005","unstructured":"Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175:2721\u20139.","journal-title":"J Immunol."},{"key":"1196_CR47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-014-0414-y","volume":"16","author":"M Frleta","year":"2014","unstructured":"Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep. 2014;16:414.","journal-title":"Curr Rheumatol Rep."},{"key":"1196_CR48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2012.10.004","volume":"69","author":"JH Peters","year":"2013","unstructured":"Peters JH, Tjabringa GS, Fasse E, de Oliveira VL, Schalkwijk J, Koenen HJ, et al. Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and ROR\u03b3t-positive IL-17 producing T-cell populations. J Dermatol Sci. 2013;69:44\u201353.","journal-title":"J Dermatol Sci."},{"key":"1196_CR49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","volume":"127","author":"CK Wong","year":"2008","unstructured":"Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127:385\u201393.","journal-title":"Clin Immunol."},{"key":"1196_CR50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12016-012-8307-1","volume":"44","author":"SP Raychaudhuri","year":"2013","unstructured":"Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183\u201393.","journal-title":"Clin Rev Allergy Immunol."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:53:20Z","timestamp":1749826400000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1196-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"296"}}